Axsome Therapeutics, Inc. (AXSM) Financial Statements (2026 and earlier)

Company Profile

Business Address ONE WORLD TRADE CENTER, 29TH FLOOR
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments322,933315,353386,193200,84286,473183,876
Cash and cash equivalent322,933315,353386,193200,84286,473183,876
Receivables224,464142,00194,82037,699  
Inventory, net of allowances, customer advances and progress billings27,93815,73215,1354,320  
Inventory27,93815,73215,1354,320  
Other undisclosed current assets13,65111,9788,1152,78145148
Total current assets:588,986485,064504,263245,64186,518184,025
Noncurrent Assets
Inventory, Noncurrent11,55510,51810,32913,708  
Finance lease, right-of-use asset, after accumulated amortization6,6004,300    
Operating lease, right-of-use asset20,8585,3836,7724206601,739
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization56258484672328453
Intangible asset, including goodwill, after accumulated amortization52,56158,93665,32869,971  
Goodwill12,04212,04212,04210,310  
Intangible asset, excluding goodwill, after accumulated amortization40,51946,89453,28659,661  
Other noncurrent assets     323317
Other undisclosed noncurrent assets8,6833,7136981,013  
Total noncurrent assets:100,81983,43483,97385,8351,2672,109
TOTAL ASSETS:689,805568,498588,236331,47687,785186,134
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities260,768186,634115,43578,92517,58516,768
Interest and dividends payable✕✕✕✕✕385394
Employee-related liabilities✕✕✕✕✕4,0502,870
Accounts payable65,53771,99740,67938,60513,14913,504
Accrued liabilities195,231114,63774,75640,320  
Debt72,5451,421    
Business combination, contingent consideration, liability10,0128,2856,4075,900  
Other undisclosed current liabilities35,51133,76417,01211,7355,4806,670
Total current liabilities:378,836230,104138,85496,56123,06523,438
Noncurrent Liabilities
Long-term debt and lease obligation121,952183,653178,07094,25949,09048,904
Long-term debt, excluding current maturities117,746180,710178,07094,25949,09048,322
Finance lease, liability4,2062,943    
Liabilities, other than long-term debt100,72297,72680,33531,100  
Operating lease, liability23,1826,0467,035  582
Business combination, contingent consideration, liability77,54091,68073,30031,100  
Other undisclosed noncurrent liabilities      (582)
Total noncurrent liabilities:222,674281,379258,405125,35949,09048,904
Total liabilities:601,510511,483397,259221,92072,15572,341
Equity
Equity, attributable to parent88,29557,015190,977109,55615,630113,793
Common stock555444
Additional paid in capital1,394,2511,179,7971,026,543705,885424,826392,585
Accumulated deficit(1,305,961)(1,122,787)(835,571)(596,333)(409,199)(278,796)
Total equity:88,29557,015190,977109,55615,630113,793
TOTAL LIABILITIES AND EQUITY:689,805568,498588,236331,47687,785186,134

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues638,496385,693270,60050,037  
Cost of revenue(47,478)(60,393)(74,983)(5,200)  
Cost of product and service sold(47,478)(33,303)(26,065)(5,198)  
Gross profit:591,018325,300195,61744,837  
Operating expenses(760,253)(605,862)(427,442)(221,340)(124,707)(99,141)
Other undisclosed operating income (loss)2,473  (3,296)  
Operating loss:(166,762)(280,562)(231,825)(179,799)(124,707)(99,141)
Nonoperating expense
(Investment Income, Nonoperating)		(6,557)(6,569)(6,453)(7,335)(5,696)(2,566)
Interest and debt expense(10,385)(320)   (1,717)
Loss from continuing operations before equity method investments, income taxes:(183,704)(287,451)(238,278)(187,134)(130,403)(103,424)
Other undisclosed income from continuing operations before income taxes 320    
Loss from continuing operations before income taxes:(183,704)(287,131)(238,278)(187,134)(130,403)(103,424)
Income tax expense (benefit)530(85)(960)   
Loss from continuing operations:(183,174)(287,216)(239,238)(187,134)(130,403)(103,424)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(130,403)(103,424)
Other undisclosed net income      523
Net loss available to common stockholders, diluted:(183,174)(287,216)(239,238)(187,134)(130,403)(102,901)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(183,174)(287,216)(239,238)(187,134)(130,403)(102,901)
Comprehensive loss, net of tax, attributable to parent:(183,174)(287,216)(239,238)(187,134)(130,403)(102,901)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: